Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, methyl ester, (11β,16α,17α)- (9CI)

Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, methyl ester, (11β,16α,17α)- (9CI) Struktur
37927-04-1
CAS-Nr.
37927-04-1
Englisch Name:
Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, methyl ester, (11β,16α,17α)- (9CI)
Synonyma:
Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, methyl ester, (11β,16α,17α)- (9CI)
CBNumber:
CB811363174
Summenformel:
C25H33FO6
Molgewicht:
448.53
MOL-Datei:
37927-04-1.mol

Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, methyl ester, (11β,16α,17α)- (9CI) Eigenschaften

Siedepunkt:
537.7±50.0 °C(Predicted)
Dichte
1.24±0.1 g/cm3(Predicted)
pka
12.91±0.70(Predicted)

Sicherheit

Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, methyl ester, (11β,16α,17α)- (9CI) Chemische Eigenschaften,Einsatz,Produktion Methoden

Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, methyl ester, (11β,16α,17α)- (9CI) Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, methyl ester, (11β,16α,17α)- (9CI) Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 3)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Wuhan Jingkang en Biomedical Technology Co., Ltd
+8613720134139
orders@jknbiochem.com China 5225 58
LangFangshi Zekang Pharma Tech CO.,Itd. 0316-2883536 19333636468
93618484@qq.com China 1321 58
Shanghai Easy CDMO Co.,Ltd 021-61734564
August@easycdmo.com China 10010 58

  • Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, methyl ester, (11β,16α,17α)- (9CI)
  • 37927-04-1
Copyright 2019 © ChemicalBook. All rights reserved